Travere Therapeutics, Inc. filings document a rare-disease biopharmaceutical issuer whose disclosures center on FILSPARI (sparsentan), operating results, FDA regulatory events, and public-company governance. Recent 8-K reports furnish quarterly and annual financial results and disclose regulatory events involving FILSPARI in focal segmental glomerulosclerosis and IgA nephropathy.
Proxy materials cover annual meeting voting, board matters, executive compensation, equity awards, and stockholder governance. The filing record also documents formal event reporting under the Exchange Act for product-regulatory updates and financial-condition disclosures.
Jula Inrig filed a Form 144 reporting dispositions of Common stock. The filing lists a 20,000-share sale on 05/04/2026 for $900,000, plus prior sales of 7,215 shares on 04/14/2026 for $302,515.98 and 1,018 shares on 04/15/2026 for $43,376.98. The form also shows 2,174 shares tied to Performance Restricted Stock Unit vesting on 05/04/2026.
TVTX reported an intended sale of 2,174 shares of Common Stock in a Form 144 related to Performance Restricted Stock Unit Vesting dated 05/04/2026. The filer also disclosed a prior sale by Peter Heerma of 7,215 shares on 04/14/2026 for $302,515.98.
Roy Baynes reported a proposed sale of 4,500 shares of Common Stock under Rule 144 tied to a stock option exercise dated 05/05/2026. The filing also lists three prior open-market dispositions by Roy Baynes: 9,750 shares on 05/01/2026 for $431,145.00; 32,750 shares on 04/14/2026 for $1,352,130.00; and 10,000 shares on 04/06/2026 for $330,000.00.
Travere Therapeutics is offering $400,000,000 aggregate principal amount of % convertible senior notes due 2032, with an underwriter option for up to $60,000,000 additional notes, subject to completion. The notes mature on May 15, 2032, bear stated cash interest (rate not specified in the excerpt) payable semi-annually, and are convertible into cash, shares of common stock or a combination at Travere’s election under specified conditions.
Conversion is permitted only upon specified triggers including a sustained common-stock price condition, a note trading-price test, certain corporate events, a call for redemption and during a conversion period beginning February 17, 2032. Notes are redeemable at Travere’s option on or after May 21, 2029 if Nasdaq trading thresholds are met. The notes will be unsecured senior obligations and will rank equal with other unsecured indebtedness and be structurally subordinated to subsidiaries’ liabilities. Travere does not intend to list the notes; its common stock traded at $44.91 on May 4, 2026. This prospectus supplement is preliminary and subject to completion (dated May 5, 2026).
Travere Therapeutics reported higher revenue but continued losses for the quarter ended March 31, 2026. Total revenue reached $127.2 million, up from $81.7 million a year earlier, driven mainly by FILSPARI sales.
Net product sales were $124.5 million, including $105.2 million from FILSPARI and $19.3 million from tiopronin products. The company recorded a net loss of $37.1 million, versus $41.2 million in the prior-year quarter, or $(0.40) per share.
Operating expenses rose to $164.1 million, reflecting higher research and development and selling, general and administrative costs, as well as royalty expense. Travere ended the quarter with $78.4 million in cash and cash equivalents and $186.3 million in marketable debt securities, against $312.1 million of convertible debt.
In April 2026, after quarter-end, the FDA granted full approval of FILSPARI for FSGS, making it the first approved medicine for this disease. Travere also restarted enrollment in its Phase 3 HARMONY study of pegtibatinase for classical homocystinuria and dosed the first new patient following the restart.
Travere Therapeutics, Inc. director Roy D. Baynes carried out an exercise-and-sell transaction involving company stock. On May 1, 2026, he exercised stock options to acquire 9,750 shares of common stock at $6.82 per share, then sold 9,750 shares in an open-market transaction at $44.22 per share.
The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on November 17, 2025, indicating it was scheduled in advance. Following these transactions, Baynes directly holds 37,500 shares of Travere common stock, and the exercised option is now fully vested and exercisable with no remaining derivative position from that specific grant.
Travere Therapeutics reported strong first quarter 2026 growth driven by FILSPARI. Total revenue was $127.2 million, up from $81.7 million a year earlier, as U.S. net product sales rose to $124.5 million, largely from FILSPARI. GAAP net loss narrowed to $37.1 million, or $0.40 per share, while non-GAAP results improved to net income of $4.1 million, or $0.05 per share. FILSPARI U.S. net product sales reached $105.2 million, an 88% year-over-year increase, supported by 993 new patient start forms for IgA nephropathy. The FDA also approved FILSPARI for focal segmental glomerulosclerosis, expanding the U.S. addressable population for FILSPARI to more than 100,000 patients. Travere restarted enrollment in its Phase 3 HARMONY Study of pegtibatinase for classical homocystinuria and ended the quarter with $264.7 million in cash, cash equivalents and marketable securities.
Morgan Stanley Smith Barney LLC filed a Form 144 notice for the proposed sale of 20,000 shares of Common Stock related to a stock option exercise to occur on 05/04/2026 with cash proceeds. The filing lists multiple sales by Elizabeth Reed during the prior three months, including 37,500 and other dispositions with aggregate proceeds shown per line items.
TVTX filing a Rule 144 notice reporting a stock option exercise and planned sale of 20,000 shares on 05/04/2026. The form lists cash settlement for the exercise. The filing also discloses prior sales in the last three months: 1,018 shares on 04/15/2026 and 7,215 shares on 04/14/2026, with dollar amounts shown for each transaction.